Influence of valproic acid on the expression of various acyl‐CoA dehydrogenases in rats

Abstract Background: Valproic acid (2‐propyl‐N‐pentanoic acid, VPA) causes severe hepatic dysfunction, similar to Reye’s syndrome, in a small number of patients. An enhanced excretion of dicarboxylic acids by patients indicates an interference with mitochondrial β‐oxidation. We investigated the expression of various acyl‐coenzyme A (acyl‐CoA) dehydrogenases (ACD), which catalyze the first step of β‐oxidation in VPA‐treated rats.

[1]  G. Finocchiaro,et al.  The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. , 1990, Biochimica et biophysica acta.

[2]  D. Turnbull,et al.  The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats. , 1983, Biochemical pharmacology.

[3]  C. Dabrowski,et al.  Separation and properties of five distinct acyl-CoA dehydrogenases from rat liver mitochondria. Identification of a new 2-methyl branched chain acyl-CoA dehydrogenase. , 1983, The Journal of biological chemistry.

[4]  Y. T. Chen,et al.  Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: diagnosis by acylcarnitine analysis in blood. , 1993, American journal of human genetics.

[5]  T. Browne,et al.  Drug therapy: Valproic acid. , 1980, The New England journal of medicine.

[6]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[7]  S. Servidei,et al.  Late onset lipid storage myopathy due to multiple acyl CoA dehydrogenase deficiency triggered by valproate , 1991, Neuromuscular Disorders.

[8]  S. Kolvraa,et al.  The occurrence of C6--C10-dicarboxylic acids in urine from patients and rats treated with dipropylacetate. , 1980, Biochemical medicine.

[9]  K. Tanaka,et al.  Purification and characterization of isovaleryl coenzyme A dehydrogenase from rat liver mitochondria. , 1983, The Journal of biological chemistry.

[10]  K Tanaka,et al.  Purification and characterization of short-chain, medium-chain, and long-chain acyl-CoA dehydrogenases from rat liver mitochondria. Isolation of the holo- and apoenzymes and conversion of the apoenzyme to the holoenzyme. , 1985, The Journal of biological chemistry.

[11]  G. Granneman,et al.  The Hepatotoxicity of Valproic Acid and Its Metabolites in Rats. II. Intermediary and Valproic Acid Metabolism , 1984, Hepatology.

[12]  F. Dreifuss,et al.  Valproic acid hepatic fatalities. III. U.S. experience since 1986 , 1996, Neurology.

[13]  Carnitine Metabolism in Valproate-Treated Rats: The Effect of L-Carnitine Supplementation , 1987, Pediatric Research.

[14]  J. McGarry,et al.  An improved and simplified radioisotopic assay for the determination of free and esterified carnitine. , 1976, Journal of lipid research.

[15]  G. Granneman,et al.  The Hepatotoxicity of Valproic Acid and Its Metabolites in Rats. I. Toxicologic, Biochemical and Histopathologic Studies , 1984, Hepatology.

[16]  K. Tanaka,et al.  Molecular cloning and nucleotide sequence of cDNAs encoding the precursors of rat long chain acyl-coenzyme A, short chain acyl-coenzyme A, and isovaleryl-coenzyme A dehydrogenases. Sequence homology of four enzymes of the acyl-CoA dehydrogenase family. , 1989, The Journal of biological chemistry.

[17]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[19]  C. Schnaitman,et al.  ENZYMATIC PROPERTIES OF THE INNER AND OUTER MEMBRANES OF RAT LIVER MITOCHONDRIA , 1968, The Journal of cell biology.

[20]  K. Tanaka,et al.  Developmental, nutritional, and hormonal regulation of tissue-specific expression of the genes encoding various acyl-CoA dehydrogenases and alpha-subunit of electron transfer flavoprotein in rat. , 1993, The Journal of biological chemistry.

[21]  N. Gerber,et al.  Reye-like syndrome associated with valproic acid therapy. , 1979, The Journal of pediatrics.

[22]  J. Carroll,et al.  A single therapeutic dose of valproate affects liver carbohydrate, fat, adenylate, amino acid, coenzyme A, and carnitine metabolism in infant mice: possible clinical significance. , 1985, Life sciences.

[23]  N. Khan,et al.  Regulation of calcium signalling by docosahexaenoic acid in human T-cells. Implication of CRAC channels. , 2000, Journal of lipid research.

[24]  C. Angelini,et al.  Carnitine deficiency, organic acidemias, and Reye's syndrome , 1985, Neurology.

[25]  T. Baillie,et al.  Inhibition of medium-chain fatty acid beta-oxidation in vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid. , 1985, Biochemical and biophysical research communications.

[26]  R. Diasio,et al.  Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Possible relevance to regional chemotherapy. , 1991, Biochemical pharmacology.

[27]  S. Schneider.  Valproic acid , 1980, The Western journal of medicine.

[28]  K. Tanaka,et al.  FAD-dependent regulation of transcription, translation, post-translational processing, and post-processing stability of various mitochondrial acyl-CoA dehydrogenases and of electron transfer flavoprotein and the site of holoenzyme formation. , 1992, The Journal of biological chemistry.